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An immunocompetent patient with a recurrence-free
Epstein-Barr virus positive plasmacytoma possesses
robust Epstein-Barr virus specific T-cell responses 
Plasmacytomas are classified as plasma cell neoplasms
and primarily occur in the bone or within soft tissue.
Extramedullary plasmacytomas (EMP) represent 3-5% of
all plasmacytomas and are commonly found in the upper
respiratory tract.1 Plasmacytomas and other plasma cell
neoplasms express CD138 and are CD20 negative based
on immunohistochemistry.2 They are further distin-
guished from plasmablastic lymphoma (PBL) and margin-
al zone lymphoma (MZL) by their morphology.
Approximately 15% of EMPs progress to plasma cell
myeloma,3 and this transition might be associated with
poor immune control. Several studies indicate an associ-
ation between plasma cell neoplasms and viral infection,
especially for human immunodeficiency virus and hepa-
titis C virus, but rarely with Epstein-Barr virus (EBV).4-6
EBV has been implicated in malignancies in immunocom-
promised individuals, including PBLs,7 which are distinct
from plasmacytomas and have poorer outcomes.
Approximately 17% of plasmacytomas found in the head
and neck region are EBV+.8 CD8+ T cells have been impli-
cated in EBV control. In particular, primary immunodefi-
ciencies that compromise CD8 development, co-stimula-
tion, and effector function predispose individuals to
uncontrolled EBV infection;9 CD8+ T-cell depletion result-
ed in higher viral loads and tumor burdens in humanized
mice10 and the adoptive transfer of EBV-specific T cells
provide favorable outcomes for post-transplant lympho-
proliferative disease (PTLD) patients.11
EBV is prevalent in more than 90% of the adult human
population. EBV maintains lifelong latent infection in
memory B cells from which it periodically reactivates.11
EBV expresses more than eighty lytic gene products and
only eight latent EBV antigens.12 There are several latency
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Figure 1. Identification of a plasmacytoma. Immunohistochemistry on paraffin-
embedded sections examining H&E staining (A), CD138 expression on the tumor sec-
tion (brown) (B), IRF4 expression in the nucleus (C), the Ki67 proliferative index as indi-
cated by Mib-1 staining (D), light chain restriction (E), PAX5 expression (F), and CD20
expression (G). Scale bars are 50 mm in length. Additional materials and methods can
be found in the Online Supplementary Materials.
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stages (Type III, II, I/0) that are distinguished as follows:
all eight latent proteins (EBNA-1, -2, -3A-C, -LP, LMP1,
and 2) are expressed by proliferative B cells during laten-
cy type III; type II latency is characterized by the expres-
sion of LMP1/2 and EBNA1, while type I latency is char-
acterized by EBNA1 alone. 
The immunology of EBV+ plasmacytomas has not been
extensively studied. Loghavi et al. described four patients
with EBV+ plasmacytomas that were EBER+, LMP1-, and
had CD8+ tumor infiltrates.13 Interestingly, while they
proposed that the infiltrating CD8+ T cells might result in
favorable patient outcomes, they did not assess EBV-spe-
cific T-cell reactivity. We have now identified an
immunocompetent individual with an EBV+ plasmacy-
toma whose tumor and PBMCs have been examined
using immunohistochemistry and for EBV-specific T-cell
reactivity, respectively, and who continues to be recur-
rence-free. 
Our patient was a 51-year-old immunocompetent
Caucasian Swiss male living in Ghana who had a wart-
like tumor in his right nasal cavity that was diagnosed as
an EBV+ extramedullary plasmacytoma in 2014. The lab-
oratory and clinical examinations showed no signs of
hypercalcemia, renal insufficiency, peripheral lym-
phadenopathy, or bone lesions. The patient was mildly
anemic (124 g/L) and had slightly decreased peripheral
lymphocytes (19.7%). No abnormal protein was found in
the urine or blood (immunofixation negative). A staging
examination with CT scan showed no systemic involve-
ment. A benign tumor was found incidentally on the left
adrenal gland, but without any discernible endocrine
effects. This patient has had recurrent malaria infections:
one serious infection in 1989, and less serious infections
every two to three years thereafter. He is HIV, HBV, and
HCV negative, has no transplantation history, and
appears immunocompetent. 
The tumor was surgically removed from the mucous
membranes of the ethmoid sinus and examined by
immunohistochemistry. The tumor consisted of medium-
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Figure 2. CD8+ cells infiltrate the patient EBV+ plasmacytoma. Immunohistochemistry on paraffin-embedded sections examining the proximity of EBER+ cells
(brown) with CD8+ cells (pink) at multiple magnifications and in different areas of the tumor (A-C) as well as CD56 expression (brown) (D). LMP1+ cells (brown)
and MHC class I+ cells (pink) were examined for obvious MHC class I surface level differences (E). The infiltration and morphology of CD4+ cells (brown) were
examined (F). White arrows indicated CD8bright T cells in proximity of blood vessels in A and at the tumor edge in B, and CD8dim, possibly NK cells in C. All images
are displayed using a 40x magnification. Scale bars are 50 mm in length.
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sized cells with round nuclei as well as smaller infiltrating
lymphocytes (Figure 1A). The tumor cells expressed both
CD138 (Figure 1B) and IRF4 (Figure 1C), indicating the
presence of plasma cells. These plasma cells had a mature
plasmacytic rather than plasmablastic morphology. We
found 10-20% of Ki67+ proliferating cells (Figure 1D) and
the tumor was negative for MYC rearrangement by fluo-
rescence in situ hybridization analysis (data not shown),
which excluded a PBL diagnosis. The tumor was kappa
chain-restricted (Figure 1E) and IgA+ (data not shown).
Importantly, the tumor was PAX5 negative (Figure 1F),
cyclin D1 negative (data not shown), and few infiltrating
lymphocytes expressed CD20 (Figure 1G). These data
together excluded MZL and MALT lymphoma. The
tumor was KSHV negative (data not shown), ruling out a
solid variant of primary effusion lymphoma. A bone mar-
row biopsy found a mild, hyporegenerative anemia but
no infiltration by malignant plasma cells or other abnor-
malities, which further supported a plasmacytoma diag-
nosis. The tumor was EBER+ (Figure 2A-C) and LMP1+
(Figure 2E), indicating that the plasmacytoma was EBV+.
Following surgery, the patient was treated with 50 Gy of
local radiotherapy and remains recurrence-free.
Because EBV+ plasmacytomas are infrequent in
immunocompetent individuals, we further characterized
the tumor immune composition. We found a significant
CD8+ cell population (Figure 2A-C) that was localized
adjacent to EBER+ tumor cells. CD8+ cells were near
blood vessels (Figure 2A; arrows) and at the tumor
periphery (Figure 2B; arrows). Both CD8dim and CD8bright
cells were observed: the CD8dim cells may correspond to
natural killer (NK) cells (Figure 2C; arrows), and the
numerous CD8bright cells are likely CD8+ cytotoxic T cells.
Indeed, a CD56 labeling revealed the presence of NK
cells that appear similar in frequency to the CD8dim pop-
ulation (Figure 2D). These data indicated that CD8+ cells
are present and may have been actively recruited into the
tumor.
We hypothesized that the surface levels of MHC class
I molecules were altered due to plasma cell differentia-
tion of some LMP1+ cells, resulting in poor recognition of
the tumor cells. We did not observe significant differ-
ences in surface MHC class I levels on LMP1-expressing
cells (Figure 2E). Interestingly, it appeared that there were
fewer LMP1 expressing cells compared to EBER expres-
sion, confirming the fluctuating expression of this antigen
in EBV-associated lymphomas.12
We also investigated CD4+ cell infiltration within the
tumor. We found many bright, round CD4+ T cells as well
as CD4+ cells with a myeloid morphology (Figure 2F),
which could be infiltrating antigen-presenting cells such
as macrophages. These data indicated that the tumor
infiltrates included NK cells, CD8+ T cells, CD4+ T cells,
and myeloid cells. 
We hypothesized that the immune cells within the
tumor microenvironment were not fully functional, but
that upon surgical tumor removal and subsequent radio-
therapy, the patient’s immune cells were able to control
further tumor dissemination. In order to better under-
stand the patient’s immune responses towards EBV, we
performed an IFNγ-specific ELISPOT assay using the
patient’s PBMCs and two healthy EBV+ controls (HD1
and HD2) (Figure 3). Unexpectedly, we observed that the
patient had particularly robust CD4+ and CD8+ T-cell
responses to the EBNA1 C-terminus (aa 400-641) com-
pared to HD1 and HD2, and that the reactivity was spe-
cific for EBNA1 pools 1 and 3 (aa 400-461 and aa 499-
548) (Figure 3). HD1, in particular, has been documented
to have robust EBV responses to multiple peptides.
EBNA1-specific CD4+ T cells are able to mount protective
responses against EBV-transformed B cells,11 and EBNA1-
specific T cells have a protective effect against PTLD.14
EBNA1-specific CD8+ T cells were observed for certain
haplotypes, including HLA-B7.11 Both the patient and
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Figure 3. Patient PBMCs react
strongly to multiple latent EBV anti-
gens. Patient PBMCs or healthy
donor PBMCs (HD1; HD2) were plat-
ed at 150,000 cells/well to pre-
pared ELISPOT plates and the indi-
cated peptides or peptide pools
were added (see also Supplemental
Figure 1) and incubated overnight at
37°C. HD1 has been documented
to react to multiple EBV antigens.
IFNγ spots were counted using an
ELISPOT plate reader. The data were
normalized as spots per 150,000
cells.
HD1 express HLA-B7. While they both responded to an
EBNA3A-derived HLA-B7 restricted peptide (aa 379-
387), the patient had much higher CD8+ T-cell reactivity
compared to HD1. Elevated EBV-specific CD8+ T-cell
reactivity in the patient was also observed using an
EBNA3A-3C pool of immunodominant CD8+ T-cell epi-
topes (Figure 3). Interestingly, despite LMP1 expression
in the tumor, we did not observe T-cell reactivity to
LMP1 (aa 179-386), which is a weak antigen compared to
EBNA1.11 The patient did not respond to control HIV pep-
tides. In summary, we demonstrate that the patient has
robust EBV-specific responses compared to two healthy
EBV carriers. 
In this study, we provide new evidence of significant
EBV-specific immune reactivity in an immunocompetent
male with an EBV+ plasmacytoma. We excluded other
diagnoses, including PBL, MZL/MALT lymphoma, and
plasma cell myeloma. We found a significant population
of immune infiltrates that were in close proximity to
EBER+ or IRF4+ expressing cells, including CD8+ cytotoxic
T cells and NK cells, CD4+ T cells, and CD4+ myeloid
cells. T cells have been implicated in the control of EBV
infection in humans,11 and in humanized mice.10
Importantly, we demonstrated that the patient had high-
ly reactive CD8+ T-cell responses to EBNA3A, and CD4+
and CD8+ T-cell responses to EBNA3A-3C and EBNA1,
but not LMP1, despite the presence of this protein within
the tumor. While tumor-resident T cells have reduced
anti-tumor activity, one can improve this by disrupting
the immunosuppressive tumor microenvironment
through chemotherapeutics or radiation therapy.15 The
resultant cell destruction releases tumor antigens, which
can expand existing or prime new immune responses;
immunosuppressive cells in the tumor are unable to exert
their inhibitory effects as efficiently. In a recent study,
four patients with EBV+ plasmacytomas containing
CD4+and CD8+ cells had disease-free survival, however,
this study did not examine EBV-specific responses.13 We
propose that tumor removal and subsequent local radio-
therapy, together with the presence of strong EBV-specif-
ic T-cell responses, are responsible for the current healthy
status of the patient, and that examining EBV-specific 
T-cell responses might be informative for future prog-
noses.
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